Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Sanjeev Pandya, Chief Executive Officer, and Nicolas Serandour, Chief Financial Officer, informed the Company on 5 June 2015 that they individually purchased 220,000 ordinary shares of 1 penny each in the Company at 9 pence per Ordinary Share on that day.
In addition, the Company was informed on 5 June 2015 that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, purchased 1,500,000 Ordinary Shares at 9.81 pence per Ordinary Share on 3 June 2015.
Following these transactions Sanjeev Pandya now holds 590,400 Ordinary Shares representing 0.044% of the issued share capital of the Company, Nicolas Serandour now holds 220,000 Ordinary Shares representing 0.016%. Michael Bradfield now has a total beneficial interest in 122,018,510 Ordinary Shares representing 8.941%.
|
Advanced Oncotherapy Plc |
|
|
Sanjeev Pandya, CEO |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CFO |
|
|
|
|
|
Westhouse Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
|
|
|
Beaufort Securities (Joint Broker) |
|
|
Saif Janjua / Jon Levinson |
Tel: +44 20 7382 8300 |
|
|
|
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |